The Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet

Last updated: March 14, 2019
Sponsor: Medical University of Lublin
Overall Status: Active - Recruiting

Phase

N/A

Condition

Inflammation

Depression

Treatment

N/A

Clinical Study ID

NCT03877393
DS192/2019
  • Ages 18-60
  • All Genders

Study Summary

More and more evidence confirms the relationship between the gut-brain-microbiota axis and the symptoms of mood disorders. A potential pathway connecting the intestines and the brain in depression is inflammation. Interventions for reducing inflammation and restoring the integrity of the intestinal mucosa are promising approaches in patients with major depressive disorder (MDD). Gut dysbiosis and the diet containing gluten are potential factors may be factors that negatively affect the communication between intestinal and brain. Gluten has a high immunogenic potential and affinity for the intestinal mucosa layer. In patients with an abnormal reaction to gluten, the elimination diet led to improved mood symptoms. However, the relationship between gluten and depression is still poorly understood. Intestinal microbiota can affect the digestion of gluten and reduce its immunogenic potential. Studies have shown that probiotic supplementation has an anti-inflammatory effect, can lead to changes in intestinal permeability and alleviate the symptoms of depression. This evidence supports the need for co-therapy, including the elimination of gluten and the restoration of intestinal eubiosis to reduce inflammation and modulate the gut-brain-microbiota axis. The objective of the SANGUT study is to determine the impact of interventions concerning the gut-brain-microbiota axis (probiotic supplementation, gluten-free diet and their combination) on the mental state, markers of inflammation and markers of intestinal permeability in adult patients with MDD. The study will last 12 weeks and consist of four visits (V): V0 - Screening (Day 0), V1 - Baseline (up to 1 week after Screening), V2 (six weeks after Baseline), V3 - End of the study (12 weeks after Baseline). The main hypothesis is that probiotic supplementation and/or a gluten-free diet will reduce the symptoms of depression, lower the level of inflammatory markers and favourably affect the integrity of the intestinal mucosal barrier.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Outpatients aged 18-60 years old;

  2. Signed written Informed Consent Form;

  3. Meet the DSM-5 criteria for MDD;

  4. Body mass index (BMI) ≥18.5 kg/m2 and ≤30 kg/m2;

  5. MADRS (Montgomery-Asberg Depression Scale) total score at screening (V0) and atbaseline (V1) of 20 points or more (moderate or severe depression);

  6. A willingness and motivation to follow the study protocol.

Exclusion

Exclusion Criteria:

  1. Diagnosis of autoimmune, neurological, immunocompromised, thyroid, inflammatory boweldiseases, diabetes, cancers, and/or IgE-dependent allergy;

  2. Psychiatric comorbidities (except specific personality disorder) including mentalretardation, organic brain dysfunction, or addiction (except nicotine and caffeine);

  3. High risk of suicide in the investigator's opinion;

  4. An infection one month before the study baseline visit (V1);

  5. The use of antibiotics and/or probiotics three months prior to the study;

  6. Glucocorticosteroids and/or metformin treatment;

  7. Intake of any other drugs which in the investigator' opinion may affect the results ofstudy;

  8. Intake of any dietary supplementation (except for vitamin D according to the "VitaminD supplementation guidelines, 2018") which in the investigator' opinion may affect theresults of the study;

  9. Changes in a pharmacotherapy and/or psychotherapy of MDD 2 weeks before the trialentry;

  10. Electroconvulsive therapy (ECT) 12 months before the trial entry;

  11. No specific diet (e.g., elimination, vegan, reduction) and changes in physicalactivity 4 weeks before the trial entry;

  12. Pregnancy or lactation.

Study Design

Total Participants: 120
Study Start date:
April 01, 2019
Estimated Completion Date:
February 28, 2021

Connect with a study center

  • 1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin

    Lublin, 20439
    Poland

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.